Drug Target Review

OCTOBER 2, 2023

Immunopeptidomics is a rapidly expanding field at the intersection of immunology and proteomics that focuses on the identification and characterization of peptides presented by major histocompatibility complex (MHC) molecules, also known as the human leukocyte antigen (HLA), on cell surfaces.

Immune Response 105

Immune Response Vaccine Disease Research 105

Drug Target Review

DECEMBER 28, 2023

These newly formed mutated proteins are called neoantigens and they are only present on tumour cells and are not found in normal, healthy cells. These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

Chemical Biology and Drug Design

JANUARY 29, 2024

sPLA 2 inhibitors have been developed for the treatment of inflammatory and other conditions such as cardiovascular disease, arteriosclerosis and rheumatoid arthritis. Besides their roles in the degradation of phospholipids, these enzymes also play an important role in the immune response by promoting inflammation.

Small Molecule 100

Small Molecule Immune Response Treatment Disease 100

Drug Target Review

MARCH 1, 2024

In this study , we demonstrated that AMP immunotherapy can boost TCR-T cell therapy by acting directly in the lymph nodes to promote the coordination of tumour-specific T cell responses by antigen presenting cells. This combination approach resulted in durable anti-tumour T cell responses and tumour eradication.

Immune Response 105

Immune Response Therapies Vaccine Small Molecule 105

Drug Target Review

NOVEMBER 24, 2023

2 Previously, La-Beck’s research has shown that liposomes made of phospholipids and cholesterol, like those used in patients, doubled tumour size in mice by suppressing their immune response in some tumours. Macrophages were detected as the cells responsible for these negative effects.

Immune Response 111

Immune Response Pharmacy Treatment Virus 111

Chemical Biology and Drug Design

APRIL 28, 2023

The public's worry about the neglected tropical disease is growing as new foci of the illness arise, which are exacerbated by alterations in behavior, changes in the environment, and an enlarged range of sand fly vectors. Leishmania research has advanced significantly during the past three decades in a few different avenues.

Immune Response 100

Immune Response Vaccine Treatment Disease 100

SugarCone Biotech

JUNE 10, 2024

Targeting 4-1BB remained of interest to the immuno-oncology field as cell culture experiments and tumor models in mice suggested that robust anti-tumor immune responses could be triggered by anti-4-1BB antibody therapies. This is the T cell type most closely associated with anti-tumor immune responses.

Immune Response 88

Immune Response Production Regulations Clinical Trials 88

Drug Target Review

DECEMBER 13, 2023

This is likely indicative of the heterogeneous nature of the disorder, and it is this complexity and diversity of clinical presentation and effects across multiple organ systems, that has made efforts to identify genetic risk factors using traditional genomic analysis approaches extremely challenging.

Bioinformatics 145

Bioinformatics Disease Regulations Immune Response 145

Drug Target Review

JANUARY 15, 2024

Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) is the third leading cause of global deaths. The pathogenesis of COPD is based on the innate and adaptive inflammatory immune response to the inhalation of toxic particles and gases. The Pathology of Chronic Obstructive Pulmonary Disease.

Immune Response 113

Immune Response Disease Science Therapies 113

Drug Target Review

JANUARY 15, 2024

An important limitation of antibodies against tumour antigens is that these agents direct responses to molecular targets present on the surface of the cell. Figure 1: HLA Class I presentation of peptides derived from intracellular antigens. However, most of these peptides may also be presented by normal cells.

Engineering 110

Engineering DNA Virus Immune Response 110

Drug Target Review

NOVEMBER 7, 2024

Introduction Therapeutic antibodies have proven to be indispensable medicines for addressing the most debilitating diseases. Agonist antibodies of immune checkpoint regulators These represent a groundbreaking class of immunotherapeutic agents that mimic the natural function of endogenous ligands by binding to specific cell-surface receptors.

Disease 52

Disease Immune Response Regulations Engineering 52

The Pharma Data

OCTOBER 6, 2021

Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta ® (ofatumumab) and Mayzent ® (siponimod) Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS.

Immune Response 52

Immune Response Vaccine Treatment Therapies 52

The Pharma Data

OCTOBER 9, 2021

Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta ® (ofatumumab) and Mayzent ® (siponimod) Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS.

Immune Response 52

Immune Response Vaccine Treatment Therapies 52

Drug Target Review

DECEMBER 27, 2023

This interaction inhibits inflammation and immune activation, and in particular prevents macrophages from phagocytosing and destroying cancer cells. By blocking CD24 with an antibody drug, our goal is to powerfully reactivate the anti-cancer immune response and drive therapeutic efficacy.

Immune Response 105

Immune Response Science Clinical Development Drugs 105

Drug Target Review

OCTOBER 19, 2023

A potential game-changer in medicine The implications of this research are vast, potentially transforming the way we treat a variety of diseases involving both the immune and nervous systems. In the absence of IL-31, these nerve cells failed to control the immune system, leading to unchecked inflammation.

Immune Response 104

Immune Response Regulations Treatment Therapies 104

DrugBank

JULY 18, 2024

Vaccines have consistently demonstrated their efficacy in protecting people from infectious diseases. This led to the eradication of smallpox and polio – two debilitating diseases that historically caused global epidemics. Adjuvants are substances added to vaccines to enhance the immune response.

Vaccine 79

Vaccine Immune Response Clinical Trials Disease 79

Drug Target Review

JULY 11, 2023

In the quest to combat and eradicate diseases, scientists and researchers are increasingly turning to the immense potential of artificial intelligence (AI) as a tool. It was here that the Impact Medicine Fund was raised as a concept around wellness for those with disease, with the ambition of unlocking some of this vast potential.

Disease 75

Disease RNA Small Molecule Clinical Development 75

The Pharma Data

JUNE 29, 2021

A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose. There is an excellent response to a second dose, even after a 10 month delay from the first.”.

Immune Response 52

Immune Response Vaccine Virus Trials 52

Broad Institute

OCTOBER 11, 2023

He also read everything he could about her disease, including emerging evidence that suggested that the immune system could recognize and kill Merkel cell carcinoma. His mother had a presentation of the disease that suggested her immune system was already on the job.

Research 137

Research Immune Response Clinical Trials Therapies 137

Drug Target Review

SEPTEMBER 11, 2023

While the concept of removing mucins from cancer cells seems promising, mucins are present in various forms on all mammalian cells. Their findings, published in Nature Biotechnology, have broad applications as mucins are associated with many diseases, including cystic fibrosis, respiratory diseases, and viruses.

Immune Response 116

Immune Response Research Engineering Virus 116

Drug Target Review

JANUARY 15, 2024

Cancer is a disease driven by variable genetic mutations. Our innate immune system evolved to clear genetically diverse pathogens and limit host toxicity, raising the possibility that it can produce similar effects in cancer. The preclinical results demonstrated significant immune responses and tumour regression.

Treatment 105

Treatment Immune Response Therapies Clinical Trials 105

The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Using data from the MS PATHS network in the U.S.,

Vaccine 52

Vaccine Therapies Disease Immune Response 52

The Pharma Data

NOVEMBER 18, 2020

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

Conversations in Drug Development Trends

MARCH 12, 2024

Deviations from established baseline values provide insights into treatment response in certain cancer indications. In addition to being well-understood, the methods for collecting non-specific markers of disease burden are frequently cost-effective and robust, enabling your clinical program to collect data seamlessly.

Clinical Trials 72

Clinical Trials Immune Response Trials Disease 72

PLOS: DNA Science

OCTOBER 12, 2023

In the final chapter of my 2012 book The Forever Fix: Gene Therapy and the Boy Who Saved It , I predicted that the technology would soon expand well beyond the rare disease world. Gene therapy clearly hasn’t had a major impact on health care, offering extremely expensive treatments for a few individuals with rare diseases.

Therapies 69

Therapies Immune Response DNA Virus 69

Drug Target Review

JUNE 9, 2023

Neoantigen-directed T-cell therapy is a potentially powerful approach that harnesses a patient’s own immune system to fight cancer. One aspect of the collaboration focuses on screening and identification of therapeutic T-cell receptors (TCRs) to target a common shared neoantigen present in many cancer patients.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

PLOS: DNA Science

OCTOBER 19, 2023

Also recently, FDA’s Cellular, Tissue, and Gene Therapies Advisory Committe turned down a stem cell treatment for amyotrophic lateral sclerosis, aka ALS, Lou Gehrig’s disease, or motor neuron disease. ALS is a disease of adulthood, beginning typically between 40 and 70 years of age. Most ALS cases are sporadic.

Therapies 111

Therapies FDA Clinical Trials Disease 111

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 15 ISACs use small immuno-agonist molecules conjugated to the antibody to boost the immune response while minimising toxicity.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Pharma Data

DECEMBER 16, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 GAITHERSBURG, Md., 16, 2020 (GLOBE NEWSWIRE) — Novavax , Inc. About Novavax. Novavax, Inc.?(Nasdaq:

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

Drug Target Review

OCTOBER 2, 2024

Cell and gene therapies (CGTs) have made significant advancements in treating oncological diseases, with therapies like CAR-T cell treatments transforming cancer care. This approach can be highly targeted, with the potential to correct mutations that lead to specific diseases or deliver therapeutic genes to improve heart function.

Therapies 98

Therapies Disease Engineering RNA 98

NIH Director's Blog: Drug Development

JUNE 30, 2020

It’s now clear that nearly everyone who recovers from coronavirus disease 2019 (COVID-19) produces antibodies that specifically target SARS-CoV-2, the novel coronavirus that causes the infection. But there is a catch: 99 percent of the study’s participants didn’t make enough neutralizing antibodies to mount an ideal immune response.

Immune Response 52

Immune Response Virus Vaccine Research 52

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Cell Biology Clinical Trials Trials 118

The Pharma Data

SEPTEMBER 28, 2020

Australian biotech Ena Respiratory has revealed new data demonstrating that its novel nasal spray almost halted replication of the SARS-CoV-2 in animals when used as a prophylactic, showing potential to improve immune response when used alongside COVID-19 vaccines. . We’ve been amazed with just how effective our treatment has been.

Immune Response 52

Immune Response Small Molecule Virus Vaccine 52

Drug Target Review

FEBRUARY 28, 2024

Belying that earlier assumption, multiple studies have now shown γδ T cells to be very powerful components of the immune system that sit at the nexus of innate and adaptive immunity. Human γδ TCR repertoires in health and disease. gammadelta T cells link innate and adaptive immune responses. Cells 9(40):800 (2020).

Therapies 105

Therapies Engineering Molecular Biology Science 105

The Pharma Data

DECEMBER 8, 2020

Overall, the vaccine protected against symptomatic disease in 70% of cases, according to a team led by researchers from Oxford University in England. ” Previous clinical trials of the vaccine had found that the vaccine triggers antibody and T-cell immune responses, and is safe in people aged 18 and older. . TUESDAY, Dec.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

JUNE 30, 2021

Dr Karin Moestl, Vice President of the ABCD , presented the 2021 Young Scientist Award to the two winners during the ISFM ( International Society of Feline Medicine ) World Feline Congress 2021 , held virtually from June 25 to 27, 2021. . We warmly congratulate this year’s winners.” References.

Immune Response 52

Immune Response Virus Disease Doctors 52

The Pharma Data

JUNE 2, 2022

Pneumococcal disease includes pneumonia, meningitis, bloodstream infections, and milder diseases such as sinusitis and otitis media and remains a significant unmet medical need despite the availability of current pneumococcal vaccines. pneumoniae invasive disease and pneumonia in adults 50 years and above.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52